The abstract is read at the publisher; the summary is JClub's.
HH2CAR T cells targeting CD75s show cytotoxic activity against B cell lymphoma cell lines but induce little to no cytokine release, and alone cannot control tumors in vivo.
- Why it matters: Conventional CD19CAR therapy is limited by mono-specificity, so complementary targets are needed to reduce target-dependent constraints and improve safety.
- What they did: The study engineered an IgM-based CAR recognizing CD75s (α2,6-linked sialic acid–capped N-glycans) using the HH2 monoclonal antibody, then tested HH2CAR alone and combined with CD19CAR in vitro and in vivo.
- The result: While HH2CAR alone fails to control tumor progression in vivo, combining it with CD19CAR creates a functional molecule and also helps prevent potential off-tumor/on-target toxicity seen with CD19 single targeting.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.